We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Horizon Discovery (Horizon) has announced it has signed a commercial service agreement with Global Pharmaceutical company; GlaxoSmithKline relating to its X-MAN technology.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to accelerate and economize the discovery on new ‘targeted’ or ‘personalized’ cancer medicines.

The agreement contributes to the identification and characterization of novel biomarkers, disease signatures and therapeutic targets in the field of cancer ‘metabolomics’; a rapidly growing area of translational cancer research.

“Dr Chris Torrance, CEO  of Horizon says “Horizon uses the power of ‘isogenic’ human cancer models to define how tumors in specific cancer patient-populations  become dependent on certain nutrient sources and whether they generate unique metabolite signatures that can be secreted into the bloodstream. In this way, we aim to develop early-detection methods and new classes of ‘personalized’ therapeutics that may starve cancers into submission”